about
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaVisualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.Investigation of copper-azamacrocyclic complexes by high-performance liquid chromatography.Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents.Preclinical Evaluation of 18F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseIn vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects.In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands.Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studiesPreparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelatorCorrelating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell linesCharacterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse modelMonoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapySynthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.Highly-efficient and versatile fluorous-tagged Cu(I)-catalyzed azide-alkyne cycloaddition ligand for preparing bioconjugates.Copper chelation chemistry and its role in copper radiopharmaceuticals.Design of targeted cardiovascular molecular imaging probes.Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis.New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.Copper-64 Radiopharmaceuticals for Oncologic Imaging(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activityRadioactivity-synchronized fluorescence enhancement using a radionuclide fluorescence-quenched dye.Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapyChelators for copper radionuclides in positron emission tomography radiopharmaceuticalsThe chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.
P50
Q27316139-BD78865F-5A26-482D-9F10-14A5DC60525EQ27323244-8A2773F6-7B84-4A4E-BD38-D315BB58E84EQ33217051-896891D8-353A-47F7-9C84-950FB3DDFED6Q33480211-8EDDA57B-BCFB-478A-A2B3-C60E679CF5C6Q33793270-14F574A8-DCB9-4A49-A1E1-5286B9679EB5Q33821017-9D569867-A3E8-4E21-957E-9BEC33565427Q33870879-77CF7E2B-076E-4A08-A9AD-EC19FEFBEA97Q33909857-299E3303-244C-46AC-98C2-5DC8BB86858CQ34144898-C1776DFA-4094-4A2B-9ECC-9561848CA987Q34162014-74D0FACD-B01B-4A82-9282-5C080614EE18Q34473719-1A6A6601-EFAD-4C50-9A8E-47EF3B6744AEQ34519479-09DFF8CA-BE0E-4312-A28E-E0BF08D9CA1AQ34665668-2F98216F-C4D8-4B37-A1EA-F445878E1423Q34677178-74D8794F-1542-4665-8A37-070FE819FB04Q34778496-39DF0BA8-12D0-4FCF-823C-109940D78305Q34778502-861F8065-2A76-41FA-96FB-19D22159522CQ34942281-5419A84F-A998-4DFF-AF36-FA722BE36672Q35057527-31264972-A6E9-497C-B566-2C60AAD0BDFFQ35124411-59D4A8C3-E19B-4C72-9DA2-6FAA0F1AA505Q35565660-5D62E6AA-0497-40F7-BDCF-977A2DD7BFE6Q35713096-1BA5FFA7-A622-4E42-82FF-7B9E82AFCAADQ36011343-34A2DCAF-6159-4AAD-8822-6213020827CDQ36303512-A3414589-2A22-4089-8AF0-5BCA5AB33090Q36724065-0990147B-E606-4874-8307-F709D4F78CA1Q36777401-9FB4B48D-3F2C-41D3-87B6-0D2A8E5EE54CQ36901996-5C564D78-6C5B-4831-94AE-F259E43023FDQ37070582-C2B0B63B-9AC6-4F3B-A10A-EB14719BE126Q37104310-8C4CE461-E8DA-4799-B575-8686609438DCQ37126530-AA2D6BAD-BA14-4EAD-AAA2-B30F8D9AB57FQ37218456-86D76AE9-4082-4605-ACAD-F5ABE9B5E5C8Q37275264-CCE1BF0F-9F48-413D-9648-C6CDC9C84BD3Q37320501-575C94EE-C710-4707-B8CB-F8829358C6FBQ37479595-D3D285C1-529E-4B08-9193-8C587887D783Q37515861-E827D2D8-93F5-40D0-BBC5-21290A56CAA7Q37545241-C5DD9484-D7C3-415A-9C0A-30DC4B0C2579Q37545575-EBB8F860-5C97-459D-9C7E-B7C86EC31082Q37632783-CC782917-62ED-4251-B099-9E3E9784964DQ38172069-BE5680A9-3CB5-420D-B6A9-1965A28F0D0AQ38420414-2AC26639-AAFA-4C50-B568-11F3C93E1F75Q38570145-DD7FB150-FCA5-4426-B83F-6C54791FE1A6
P50
description
cardiologist
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carolyn J Anderson
@nl
Carolyn J Anderson
@sl
Carolyn J. Anderson
@en
Carolyn J. Anderson
@es
type
label
Carolyn J Anderson
@nl
Carolyn J Anderson
@sl
Carolyn J. Anderson
@en
Carolyn J. Anderson
@es
altLabel
Carolyn Joan Anderson
@en
prefLabel
Carolyn J Anderson
@nl
Carolyn J Anderson
@sl
Carolyn J. Anderson
@en
Carolyn J. Anderson
@es
P106
P1153
35515844300
P1960
cJo70mQAAAAJ
P21
P31
P496
0000-0002-5663-282X